EP0214839A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Improvements in relation to drug treatments
Assignee: Efamol Holdings PLC
•
Filing: 1986-09-03
•
Granted: —
•
Expires: 2006-09-03
Abstract
Abstract A composition comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, the composition reducing that sensitisation.
Inventors
- 👤 David Frederick C/O Efamol Ltd. Horrobin
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-09 04:32
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/185; A61K31/19; A61K31/20; A61K31/33; A61K31/395; A61K31/40; A61K31/65; A61P; A61P31/00; A61P31/12; A61P35/00; A61P9/00; A61P9/10
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
68 words
Composition of a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, said composition reducing that sensitisation.
Claim 2
Dependent Claim
68 words
Composition of a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites), together with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, alone or in a pharmaceutically acceptable diluent or carrier, said composition reducing that sensitisation.
Claim 3
Dependent Claim
62 words
Composition as in claim 1, wherein the porphyrin is HpD or a pharmacologically acceptable and especially water-soluble meso porphyrin of the formula: where n= 1 to 3 and each substituent R, the same or different and at the same or different point in its representative substituent phenyl ring or other aromatic group replacing that ring, is an hydroxy, amino or sulphhydryl group.
Claim 4
Dependent Claim
76 words
Composition according to claim 1 or claim 2 presented in dosage units suited to administration of 1 mg to 500 g of the fatty acid daily and in the case of porphyrins generally or tetracyclines or Benoxaprofen a conventional daily dose and in the case of porphyrins according to formula I as set out in claim 2 a pharmacologically acceptable and effective amount within the range 0.01 to 100 mg/kg (based on a 70 kg adult).
Claim 5
Independent Claim
92 words
A method of preparing a composition for use in conjunction with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, or for use in ameliorating the effects of spontaneous porphyrias, characterised in that said composition is prepared in a form that comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites) alone or in a pharmaceutically acceptable diluent or carrier.
Claim 6
Independent Claim
92 words
A method of preparing a composition for use in conjunction with a drug that taken alone has a side-effect of sensitising the skin to light, in particular a porphyrin or tetracycline or Benoxaprofen, or for use in ameliorating the effects of spontaneous porphyrias, characterised in that said composition is prepared in a form that comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites) alone or in a pharmaceutically acceptable diluent or carrier.
Claim 7
Dependent Claim
24 words
A method according to claim 4, wherein the prophyrin is HpD or a porphyrin according to formula I as set out in claim 2.
Claim 8
Dependent Claim
61 words
A method according to claim 4 or claim 5 wherein the amounts of said materials are 1 mg to 500 g of the fatty acid daily and in the case of porphyrins according to formula I as set out in claim 2 a pharmacologically acceptable and effective amount within the range 0.01 to 100 mg/kg (based on a 70 kg adult).
Claim 9
Dependent Claim
75 words
Composition of a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites) together with HpD or other tumour locating porphyrin including porphyrins according to formula I as set out in claim 2, alone or in a pharmaceutically acceptable diluent or carrier, suited to administration and subsequent light irradiation to destroy tumour or atheromatous or virus infected cells.
Claim 10
Dependent Claim
69 words
Composition according to claim 7 presented in dosage units suited to administration of 1 mg to 500 g of the fatty acid daily and in the case of porphyrins generally a conventional daily amount and in the case of porphyrins according to formula I as set out in claim 2 a pharmacologically acceptable and effective amount within the range 0.01 to 100 mg/kg (based on a 70 kg adult).
Claim 11
Independent Claim
79 words
A method of preparing a composition for use in enhancing the effect of administered tumour or atheromatous or virus infected cell-locating porphyrins in subsequent light irradiation to destroy said cells, characterised in that said composition is prepared in a form that comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites) alone or in a pharmaceutically acceptable diluent or carrier.
Claim 12
Independent Claim
79 words
A method of preparing a composition for use in enhancing the effect of administered tumour or atheromatous or virus infected cell-locating porphyrins in subsequent light irradiation to destroy said cells, characterised in that said composition is prepared in a form that comprises a polyunsaturated fatty acid, in particular an essential fatty acid of the n-6 series (linoleic acid or its metabolites) or the n-3 series (alpha-linolenic acid and its metabolites) alone or in a pharmaceutically acceptable diluent or carrier.
Claim 13
Dependent Claim
69 words
A method according to claim 9 wherein the amounts of said materials are 1 mg to 500 g of the fatty acid daily and in the case of porphyrins generally a conventional daily amount and in the case of porphyrins according to formula I as set out in claim 2 a pharmacologically acceptable and effective amount within the range 0.01 to 100 mg/kg (based on a 70 kg adult).
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.